Sign in

Sara R. Fagerlie, PhD, CHCP

@cancercommunicator.com
964 followers 2.1K following 249 posts

Founder of CancerCommunicator.com - Dedicated to improving the care of patients with cancer through news and clinician education.

PostsRepliesMedia
Reposted by Sara R. Fagerlie, PhD, CHCP
Myeloma Society @myeloma-society.bsky.social · 25/09/2026
We not only need to treat infections in T-cell redirecting therapy recipients, but also identify high-risk patients, their risk timing, & employ risk-adapt approaches, Paula Rodriguez-Otero, MD, PhD, said. #IMS26
132
Reposted by Sara R. Fagerlie, PhD, CHCP
Myeloma Society @myeloma-society.bsky.social · 25/09/2026
When you see improvement in overall survival with primary IVIG prophylaxis, besides reduced infection risk, this is a strategy we should adopt for T-cell redirecting therapy recipients --- Noopur Raje, MD #IMS26
141
Reposted by Sara R. Fagerlie, PhD, CHCP
Myeloma Society @myeloma-society.bsky.social · 26/09/2026
Iberdomide-Dara-dex was the first approval in myeloma based on MRD-neg CR. Sagar Lonial, MD, who presented data from ph3 EXCALIBER-RRMM trial that supported the approval, said this combination is a new std of care in RRMM. #IMS26
042
Reposted by Sara R. Fagerlie, PhD, CHCP
ESMO - European Society for Medical Oncology @myesmo.bsky.social · 22/09/2026
📣 #ESMO26: The late-breaking abstract lineup is taking shape! Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect. 🔗 ow.ly/6Res50ZQ82a
043
Reposted by Sara R. Fagerlie, PhD, CHCP
targetedonc.bsky.social @targetedonc.bsky.social · 23/09/2026
Excited to hear @nikhilmunshi.bsky.social discuss the concept of cure in myeloma! #IMS2026
111
Reposted by Sara R. Fagerlie, PhD, CHCP
Myeloma Society @myeloma-society.bsky.social · 23/09/2026
A cure for myeloma, defined. Long considered incurable, myeloma now has a consensus standard: five years off treatment with no detectable disease. “We are no longer debating whether cure is possible,” said Dr. Nikhil Munshi at #IMS26. Read more → ow.ly/GNG850ZQvKo
031
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 21/09/2026
So much important information in this survey. "When the world doesn’t invest in women’s health, that dramatically impacts how they can show up at work, at home, and in their communities" #womenshealth www.pivotal.com/articles/gal...
001
Reposted by Sara R. Fagerlie, PhD, CHCP
Nature @nature.com · 11/09/2026
The US National Science Foundation (NSF) is changing how it funds research grants — and how it decides which ones to fund — to better align with White House priorities, according to a letter released on 10 September. go.nature.com/4iXOjZI
go.nature.com
NSF moves to overhaul funding approach in line with White House priorities
The major funder of basic science has not said how its new initiatives will be funded — but staff worry streamlined approach will further squeeze cash for core sciences.
51518
Reposted by Sara R. Fagerlie, PhD, CHCP
NEJM.org @nejm.org · 13/09/2026
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: nej.md/4xKtvcF #WCLC26
This image consists of Kaplan–Meier curves for overall survival in the intention-to-treat population.
072
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 12/09/2026
$480K for daraxonrasib adds to the growing cost of cancer care, a"CAR-T therapy now goes for $600K...[another CART] is listed at $550K. A daily pill for gastrointestinal cancer has a sticker price of $520K a year. A twice-daily pill for leukemia? It’s $430K a year" www.nytimes.com/2026/08/31/b...
nytimes.com
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs (Gift Article)
Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
110
Reposted by Sara R. Fagerlie, PhD, CHCP
The Alliance @alliance4cehp.bsky.social · 11/09/2026
Heather Ranels, MA, MS, CHCP, FACEHP, offers a practical framework for selecting credible sources and for using and vetting AI outputs in the context of CPD professionals. almanac.acehp.org/Education/Ed...
almanac.acehp.org
Credible by Design: Selecting and Verifying Sources in AI-Assisted CPD
In continuing professional development (CPD) for healthcare professionals, credible sourcing is not a formality. It is central to educational integrity. The sources used to support needs assessment,…
011
Reposted by Sara R. Fagerlie, PhD, CHCP
The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2026
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.04 — A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821)
012
Reposted by Sara R. Fagerlie, PhD, CHCP
The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2026
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 — Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR-Mutated NSCLC (HARMONi): Updated Overall Survival Analysis ✅ OS benefit durable and consistent across regions, no new safety signals
022
Reposted by Sara R. Fagerlie, PhD, CHCP
The OncoAlert Network 🚨 @oncoalert.bsky.social · 10/09/2026
The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.02 A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
012
Reposted by Sara R. Fagerlie, PhD, CHCP
Jonathan Howard @joho.bsky.social · 09/09/2026
Ooops
sciencebasedmedicine.org
In 2014, Dr. Kelly Brogan and Sayer Ji Told People Natural HPV Infections Were “Beneficial, Not Deadly.” What’s Happened Since?
Pseudoscience requires apathy about its victims, and that's the most grotesque part about it.
46825
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 04/09/2026
To address new work requirements, "state Medicaid agencies have been exploring technological solutions to automate redeterminations at scale...6 agencies have decided to use AI tools so far and 21 states are considering use of them." What could go wrong? www.cancercommunicator.com/JAMA_AI_Medi...
cancercommunicator.com
Roles for AI in Implementation of Medicaid Work Requirements
This JAMA Forum discusses Medicaid work requirements after passage of the 2025 budget reconciliation law, the role of artificial intelligence (AI) in helping to determine Medicaid eligibility, and pot...
001
Reposted by Sara R. Fagerlie, PhD, CHCP
Jonathan Howard @joho.bsky.social · 02/09/2026
He’s right.
1317
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 30/08/2026
This story is more about healthcare than the headline suggests-a hospital in RI is being forced to turn over all medical records of children who received gender affirming care. What are they planning to do with that info and who will they go after next? Gift article www.nytimes.com/2026/08/30/u...
nytimes.com
How Trump’s Policy Agenda Runs Through One Federal Court, in Texas
For years, conservative litigants flocked to Judge Reed O’Connor’s district. Now, North Texas has become a favorite destination of the Justice Department.
000
Reposted by Sara R. Fagerlie, PhD, CHCP
Pancreatic Cancer Action Network @pancan.bsky.social · 26/08/2026
Visit 🔗 pancan.org/news/fda-approves-rasonq… to learn more about RASONQUE™, including what this FDA approval means, the survival benefit for people with pancreatic cancer, potential side effects, insurance coverage and how PanCAN Patient Services can help. 💜
011
Reposted by Sara R. Fagerlie, PhD, CHCP
Pancreatic Cancer Action Network @pancan.bsky.social · 27/08/2026
Thank you to The New York Times for including PanCAN Chief Scientific and Medical Officer Dr. Anna Berkenblit’s perspective on what this approval means for patients and the pancreatic cancer community. 💊 www.nytimes.com/2026/08/26/science/…
nytimes.com
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
03512
Reposted by Sara R. Fagerlie, PhD, CHCP
Nature @nature.com · 23/08/2026
This controversial surgery for Alzheimer's patients aims to improve drainage of fluid from the brain. What do we know about it? go.nature.com/4zsxmfM
go.nature.com
A controversial Alzheimer’s surgery is said to reverse symptoms — here’s what scientists know
Nature - Jaw-dropping patient videos and miraculous testimonials ignited a frenzy in China over a technique that aims to improve drainage from the brain. Now it is entering trials worldwide.
03210
Reposted by Sara R. Fagerlie, PhD, CHCP
Timothy McBride @mcbridetd.bsky.social · 22/08/2026
[Editorial] Attacks on LGBTQ+ health are a threat to all www.thelancet.com/journals/lan...
thelancet.com
Attacks on LGBTQ+ health are a threat to all
The health of LGBTQ+ people has long been an indicator of wider advances in human rights and health equity. Modern LGBTQ+ liberation movements have achieved substantial progress towards the decriminal...
0157
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 19/08/2026
Phase 3 INTerpath-001 trial of adjuvant tx with personalized mRNA vaccine intismeran autogene + pembrolizumab in resected stage IIB-IV melanoma reported positive for primary EP of RFS and secondary EP of distant dMFS by joint company press release. #moderna www.cancercommunicator.com/melanoma_mRN...
cancercommunicator.com
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wit...
First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanom...
000
Reposted by Sara R. Fagerlie, PhD, CHCP
JAMA @jama.com · 20/01/2025
Cervical cancer mortality in US women <25 years significantly declined between 2016 and 2021, likely due to the widespread adoption of HPV vaccination. ja.ma/3CfjTPI #MedSky #OncSky
Figure. Trends in Cervical Cancer Mortality Rates and Number of Cervical Cancer Deaths Among US Women Aged Younger than 25 Years, 1992-2021
415647
Reposted by Sara R. Fagerlie, PhD, CHCP
Reuters @reuters.com · 06/08/2026
US FDA approves first mRNA flu shot from Moderna reut.rs/3TZfDfI
reut.rs
US FDA approves first mRNA flu shot from Moderna
The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine ​for seasonal flu.
56721
Reposted by Sara R. Fagerlie, PhD, CHCP
Timothy McBride @mcbridetd.bsky.social · 05/08/2026
Proven childhood obesity treatment also works at pediatrician’s office - The Source - WashU source.washu.edu/2026/07/prov...
source.washu.edu
Proven childhood obesity treatment also works at pediatrician’s office
A clinical trial co-led by WashU Medicine researchers found that adding family-based behavioral treatment to specialized pediatric care helped nearly half of children with obesity reach a healthier we...
032
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 05/08/2026
Interesting article in JAMA especially when finding a provider can be challenging. Self-directed CBT for chronic pain with asynchronous, personalized feedback produced superior but small improvements in pain interference www.cancercommunicator.com/JAMA_CBT
cancercommunicator.com
Self-Directed vs Clinician-Delivered CBT for Chronic Pain
This randomized trial investigates whether a self-directed cognitive behavioral therapy for chronic pain (CBT-CP) program that provides personal feedback reduces chronic pain more effectively than CBT...
000
Reposted by Sara R. Fagerlie, PhD, CHCP
Timothy McBride @mcbridetd.bsky.social · 03/08/2026
OMB's proposed grantmaking rule will destabilize biomedical research, experts warn thehill.com/policy/healt...
thehill.com
OMB’s proposed grantmaking rule will destabilize biomedical research, experts warn
A proposed rule from the Office of Management and Budget to revise the federal grantmaking process is drawing widespread opposition from across multiple industries. Members of the medical research …
044
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 02/08/2026
I would recommend an easier allowance for seniors to one time be able to switch back to traditional medicare. Many patients dont qualify to switch back and are left with a MA plan that does not meet their needs. Gift article www.nytimes.com/2026/04/16/b...
nytimes.com
Help for Medicare Advantage Patients Who Lose Doctors Is Shelved, for Now (Gift Article)
Nationwide, hospitals and other providers are leaving private Medicare Advantage plans, putting thousands of seniors at risk of higher costs and of losing trusted doctors.
000
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 02/08/2026
Gift article. "The companies denied about 13 percent of patients’ requests to go to a skilled nursing facility to continue their recovery from surgery or a serious illness, according to the first report." Most of them subsequently overturned on appeal. www.nytimes.com/2026/06/11/b...
nytimes.com
Private Medicare Plans Often Deny Access to Rehab Care, Analysis Shows
000
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 02/08/2026
This did not get nearly the amount of attention it deserved."The decision means that millions of Americans 65 and older could face higher Medicare drug premiums next year, when the cost of living is already a major concern." Gift article www.nytimes.com/2026/07/28/b...
nytimes.com
Trump Will End Subsidies for Medicare Drug Premiums (Gift Article)
Millions of older Americans could pay more for their prescription drug coverage next year.
022
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 30/07/2026
Stability is paramount to care for elderly Americans. Medicare Advantage plans without guardrails do not provide that. Patient wellbeing is not the goal of for-profit insurers.https://www.healthcaredive.com/news/humana-2027-medicare-advantage-plan-exits-q2-2026/826441/
000
Reposted by Sara R. Fagerlie, PhD, CHCP
MedPage Today @medpagetoday.com · 29/07/2026
Last year, National Cancer Institute (NCI)-designated cancer centers were worried about losing their status. Now, leaders at these centers say the situation is more stable -- but the funding is coming through much more slowly. www.medpagetoday.com/hematologyonco…
medpagetoday.com
NIH Funding Flows Slowly to Cancer Centers
'You get nervous as you're getting into negative balances,' one center director says
011
Reposted by Sara R. Fagerlie, PhD, CHCP
Nature @nature.com · 28/07/2026
With the benefits of AI tools come fresh patient-safety risks — and questions about who is responsible when things go wrong go.nature.com/3Rv5WoB
go.nature.com
When physicians and AI work together, who is accountable? How to lay out medical liability
A staging system based on how big a role AI has in patient care can help to identify who is responsible in cases in which care fails.
3124
Reposted by Sara R. Fagerlie, PhD, CHCP
STAT @statnews.com · 28/07/2026
Growing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis. www.statnews.com/2026/07/28/p...
statnews.com
After PCOS became PMOS, there's hope for new awareness among Black and Latina women
Growing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.
0177
Reposted by Sara R. Fagerlie, PhD, CHCP
Nature @nature.com · 28/07/2026
The first volunteer was vaccinated against Ebola only 68 days after the WHO declared the current outbreak a public health emergency of international concern We spoke to the study's lead scientists about how they were able to move so fast go.nature.com/4x7jMN0
go.nature.com
Inside the high-stakes race to develop an Ebola vaccine for an escalating outbreak
The University of Oxford has already vaccinated its first clinical-trial participant. The study’s lead scientist Teresa Lambe tells Nature how they were able to move so fast.
04120
Reposted by Sara R. Fagerlie, PhD, CHCP
🦋Dr. Natalia🕊🌻🪬 @solnatamd.medsky.social · 28/07/2026
NYSNA has also voiced concerns with Datavant’s reported ties to Palantir ..The Datavant-powered National COVID Cohort Collaborative Privacy-Preserving Record Linkage runs off a Palantir scientific computing platform, Palantir Foundry,
courier-journal.com
AI is replacing nurses in NY. I fear the same fate for KY. | opinion
Replacing human nurses with AI is absurd, but it's happening in New York, with technology provided by a company with significant penetration in KY.
21913
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 27/07/2026
Does this make anyone else nervous?
000
Reposted by Sara R. Fagerlie, PhD, CHCP
ME/CFS San Diego @mecfssd.bsky.social · 04/07/2025
Many U.S. people don’t realize their child(ren)’s insurance is CHIP, especially when it goes by a different name in their state or territory. ME/CFS San Diego created a list to help: 🔗 www.reddit.com/r/mecfsSD/co...
CHIP Program Names by State & Territory (2025)
State / Territory CHIP Program Name(s)
Alabama ALL Kids
Alaska Denali KidCare
Arizona KidsCare
Arkansas ARKids First!
California Medi‑Cal for Kids
Colorado Child Health Plan Plus (CHP+)
Connecticut HUSKY B (under HUSKYHealth)
District of Columbia DC Healthy Families
Delaware Diamond State Health Plan Plus
Florida Florida KidCare
Georgia PeachCare for Kids
Hawaii Med‑QUEST
Idaho Idaho Medicaid (includes CHIP)
Illinois All Kids
Indiana Hoosier Healthwise
Iowa Healthy and Well Kids in Iowa (hawk-i)
Kansas KanCare (includes CHIP component)
Kentucky Kentucky CHIP (KCHIP)
Louisiana LaCHIP
Maine Cub Care
Maryland Maryland Children’s Health Program (MCHP)
Massachusetts MassHealth (includes CHIP)
Michigan MIChild
Minnesota MinnesotaCare (includes CHIP)
Mississippi Mississippi CHIP
Missouri MO HealthNet for Kids
Montana Healthy Montana Kids
Nebraska Kids Connection
Nevada Nevada Check Up
New Hampshire NH Medicaid (includes CHIP)
New Jersey NJ FamilyCare (includes CHIP)
New Mexico Centennial Care for Children
New York Child Health Plus (ChPlus)
North Carolina NC Health Choice for Children
North Dakota Healthy Steps
Ohio Healthy Start (CHIP)
Oklahoma SoonerCare (includes CHIP)
Oregon Oregon Health Plan (includes CHIP)
Pennsylvania CHIP
Rhode Island RIte Care (includes CHIP)
South Carolina Healthy Connections Kids
South Dakota CHIP
Tennessee CoverKids
Texas Children's Health Insurance Program (under HHSC)
Utah Utah CHIP
Vermont Dr. Dynasaur
Virginia FAMIS (Family Access to Medical Insurance Security)
Washington Apple Health for Kids
West Virginia WV CHIP
Wisconsin BadgerCare Plus (includes CHIP)
Wyoming KidCare CHIP

Puerto Rico: Mi Salud (Medicaid + CHIP integrated)
Guam: Guam CHIP Program
American Samoa: American Samoa CHIP
Northern Mariana Islands: CNMI CHIP (waiver under §1902(j))
U.S. Virgin Islands: Medical Assistance Program (includes CHIP)
02314
Reposted by Sara R. Fagerlie, PhD, CHCP
NEJM.org @nejm.org · 13/07/2026
Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Read the full TRANSCEND trial results: nej.md/3Rm9E3L
061
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 13/07/2026
"the American Astronomical Society said the endeavor cannot be considered to serve the public interest and would waste taxpayer $ by wrecking the work of federally funded astronomical facilities even as it brought untold risks to people and wildlife" Gift article. www.nytimes.com/2026/07/10/c...
nytimes.com
F.C.C. Approves Test of Space Mirror to Light Night Sky Despite Outcry (Gift Article)
A start-up company has permission to try its plan to bounce solar rays onto the dark side of Earth, turning night to day for a three-mile-wide patch.
81771367
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 07/07/2026
Gift article www.nytimes.com/2026/07/06/u...
nytimes.com
Decline of Ph.D. Admissions Could Imperil a ‘Generation of New Talent’
055
Reposted by Sara R. Fagerlie, PhD, CHCP
American Society of Clinical Oncology @ascocancer.bsky.social · 02/07/2026
🎙️ Dr. Megan Kruse of @clevelandclinic.bsky.social and ️@hoperugo.bsky.social of @cityofhope.bsky.social share key takeaways on OPTIMA and other major #ASCO26 breast cancer studies on the latest episode of the #ASCODailyNews Podcast: bit.ly/4apPEUm
021
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 29/06/2026
"The [AI] tool checks every application’s title, abstract and other summary sections for terms including ‘racism’, ‘fossil fuel’, ‘queer’ and ‘sexual minorit’" after passing 2 rounds of peer review, and after programme officials and the relevant institute director have agree #medsky #NIH
000
Reposted by Sara R. Fagerlie, PhD, CHCP
Dana-Farber Cancer Institute @danafarber.bsky.social · 25/06/2026
Yesterday, the @fda.gov approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer. This action is based on results from the ASCENT-03 & -04 global clinical trials, which @stolaney1.bsky.social helped to lead. ➡️ bit.ly/4uZoDP0
Sara Tolaney, MD, MPH
043
Reposted by Sara R. Fagerlie, PhD, CHCP
Medthority @medthority.bsky.social · 24/06/2026
Catch up on key data from #EHA2026 highlighting advances in thrombotic and bleeding risk stratification, including validation of thrombotic risk models, machine learning–based bleeding prediction tools, and comparative anticoagulation outcomes in hematologic populations ow.ly/ThjF50Zfk2R
011
Reposted by Sara R. Fagerlie, PhD, CHCP
Science Magazine @science.org · 22/06/2026
Exclusive: The National Science Foundation is trimming this year’s budgets for hundreds of its traditional basic science programs by roughly 20% to 30%, even though its overall budget is down just 3%. scim.ag/4xY2KCm
science.org
Exclusive: NSF slashes research programs to support new tech initiative, insiders say
Unexpected shift in funds has meant sharp drop in grants this fiscal year
10345290
Reposted by Sara R. Fagerlie, PhD, CHCP
Alex Wild @alexwild.bsky.social · 22/06/2026
Yeah, fuck this. Our public money is essentially being diverted from science to supporting the stock prices of ruling party donors.
10756258
Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 21/06/2026
"Less support for scientists means strange questions no one will get to chase. Exploring those questions is how medicine advances." #medsky
000
Reposted by Sara R. Fagerlie, PhD, CHCP
David Blanchflower BSc @davidbflower.bsky.social · 18/06/2026
Cervical cancer deaths fall to zero in young women given vaccine. 🧪 www.bbc.co.uk/news/article...
bbc.co.uk
Cervical cancer deaths fall to zero in young women given vaccine
A new study finds that hundreds of lives have been saved since school-age girls were offered the HPV jab in 2008.
10959461800